Rodolfo Alejandro

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Rodolfo Alejandro sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 3 currently recruiting 7 completed early-phase tilt top decile by trial count

Rodolfo Alejandro: 10 sponsored US clinical trials, 3 recruiting.

Rodolfo Alejandro sponsors 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 3 trials.

Top-decile sponsor footprint

Rodolfo Alejandro ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Rodolfo Alejandro pipeline

3 recruiting of 10 indexed (30% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Type 1 Diabetes Mellitus (3 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Rodolfo Alejandro: open-pipeline peers nationwide

Peers matched on 10 registered trials and 30% open enrollment, not the therapeutic-area sidebar.

Rodolfo Alejandro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 9.99.91010.1 0%10%20%30%40% Total trials Recruiting share Rodolfo AlejandroAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsCentre hospitalier de l'Université de Montréal (CHUM)Child TrendsJacques E. ChellyJason Sperry
Rodolfo Alejandro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rodolfo Alejandro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 30% open enrollment (± trial volume)

What to do with this Rodolfo Alejandro page

10 registered trials is a research-attention snapshot, not an endorsement of Rodolfo Alejandro or any single study.

  • 3 of Rodolfo Alejandro's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes Mellitus is the condition Rodolfo Alejandro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rodolfo Alejandro pipeline card: 10 registered trials from official public datasets.Report a data error.